A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.
The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers.
Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028.
The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.
The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and ...
The Centers for Medicare and Medicaid Services said Tuesday it seeks to lower Medicare costs for 16 medications by negotiating with their manufacturers. Among them is Biktarvy, a drug taken after HIV ...
In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming price cuts under the Inflation Reduction Act (IRA), AbbVie is the late | The ...
The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.
AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results